logo
Blog
  • eSource DDC
  • eCOA
  • ePRO
  • eConsent
  • BYOD
  • |
  • Back to clinicalink.com

Category: Oncology

Oncology / ePRO / eCOA

Agile Lunexis™ ePRO+ Methodology: Eliminating Barriers to Cancer Research

Read More
Kim Romanello Kim Romanello January 25, 2021

Receive Industry Updates
SUBSCRIBE TO OUR BLOG

Filter By Category

  • BYOD (2)
  • CNS (2)
  • eCOA (14)
  • eCOA/ePRO (1)
  • eConsent (2)
  • ePRO (12)
  • eSource DDC (7)
  • Gastrointestinal (1)
  • Infectious Disease (2)
  • Lupus (3)
  • Oncology (1)
See all

Filter By Author

  • Doug Pierce (7)
  • Ed Seguine (3)
  • Jonathan Andrus (8)
  • Kim Romanello (3)
  • Rinah Yamamoto (1)
  • Tess Dugan (1)
See all

Popular Articles

eSource DDC

DDC vs. EDC: Frequently Asked Questions

eSource DDC

eSource: 6 Steps to Understanding

More From Clinical Ink

Screen Shot 2020-12-15 at 10.23.01 AM-1 Fact Sheet

Virtual Trials: Trust in Experience, Trust in Lunexis™

ClinicalInk_WhitePaper_GI_7-7-20_VF_Cover-1 White Paper

Improve GI Data and Patient Engagement With GI ePRO/eCOA

Clinical-Ink_Successful-BYOD_screenshot White Paper

Successful BYOD in Any Phase

More Articles

All posts

About Clinical Ink

Clinical Ink, a global clinical technology company, offers data certainty from source to submission. Our Lunexis™ eSource clinical technology and configurable direct data capture, eCOA, patient engagement, telehealth, eConsent, and instrumented data collection modules provide a suite of solutions for capturing and integrating electronic data from sites, clinicians, caregivers, and patients at its source. Clinical Ink’s therapeutic-area-specific approach to study design and data capture — with specific expertise in neurocognitive testing — enables more precise scales for cognitive and human factors assessments, including performance, behavior, movement, and all real-world activity.